Aspirin-/TMZ-coloaded Microspheres Exert Synergistic Antiglioma Efficacy via Inhibition of β-catenin Transactivation

CNS Neuroscience and Therapeutics

Volumn 19, Issue 2, 2013, Pages 98-108

  Shi, Zhen Dong ^a,b   Qian, Xiao Min ^c   Liu, Chao Yong ^c   Han, Lei ^a,b   Zhang, Kai Liang ^a,b   Chen, Lu Yue ^a,b   Zhang, Jun Xia ^a,b   Pu, Pei Yu ^a,b   Yuan, Xu Bo ^c   Kang, Chun Sheng ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c TIANJIN UNIVERSITY   (China)

Author keywords

catenin; Aspirin; Combination chemotherapy; Microspheres; TMZ

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; CTNNB1 PROTEIN; MICROSPHERE; POLYGLACTIN; PROTEIN; PROTEIN KINASE B; PROTEIN KINASE B BETA; STAT3 PROTEIN; TCF4 PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ASPIRIN; BETA CATENIN; CELL LINE, TUMOR; DACARBAZINE; DRUG CARRIERS; DRUG SYNERGISM; GLIOMA; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSPHERES; RANDOM ALLOCATION; TRANSCRIPTIONAL ACTIVATION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872688686     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12041     Document Type: Article

References (41)

1. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 2006;17:247-289.
2. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011;3:1377-1397.
3. Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008;2:1696-1702.
4. Zou GK, Song YL, Zhou W, et al. Effects of local delivery of bFGF from PLGA microspheres on osseointegration around implants in diabetic rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2012;114:284-289.
5. Ahmed AU, Tyler MA, Thaci B, et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharmaceut 2011;8:1559-1572.
6. Mrugala MM, Chamberlain MC. Mechanisms of disease: temozolomide and glioblastoma-look to the future. Nat Clin Pract Oncol 2008;5:476-486.
7. Agnihotri S, Gajadhar AS, Ternamian C, et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest 2012;122:253-266.
8. Motomura K, Natsume A, Wakabayashi T. Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas. J Neurooncol 2012;106:209-211.
9. Andrasi M, Bustos R, Gaspar A, Gomez FA, Klekner A. Analysis and stability study of temozolomide using capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:1801-1808.
10. Sarkaria JN, Kitange GJ, James CD, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 2008;14:2900-2908.
11. Qian X, Ren Y, Shi Z, et al. Sequence-dependent synergistic inhibition of human glioma cell lines by combined Temozolomide and miR-21 inhibitor gene therapy. Mol Pharmaceut 2012;9:2636-2645.
12. Dinarello CA. Anti-inflammatory agents: present and future. Cell 2010;140:935-950.
13. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-899.
14. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010;28:1467-1472.
15. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-658.
16. Lan F, Yue X, Han L, et al. Antitumor effect of aspirin in glioblastoma cells by modulation of beta-catenin/T-cell factor-mediated transcriptional activity. J Neurosurg 2011;115:780-788.
17. Han L, Yue X, Zhou X, et al. MicroRNA-21 Expression is regulated by beta-catenin/STAT3 Pathway and Promotes Glioma Cell Invasion by Direct Targeting RECK. CNS Neurosci Ther 2012;18:573-583.
18. Jin ZJ. About the evaluation of drug combination. Acta Pharmacol Sin 2004;25:146-147.
19. Chen L, Han L, Zhang K, et al. VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1alpha/VEGF and beta-catenin/Tcf-4 signaling. Neuro Oncol 2012;14:1026-1036.
20. Li C, Zhou C, Wang S, et al. Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3beta/beta-catenin signaling pathway. PLoS ONE 2011;6:e27053.
21. Chen L, Huang K, Han L, et al. Beta-catenin/Tcf-4 complex transcriptionally regulates AKT1 in glioma. Int J Oncol 2011;39:883-890.
22. Zhang J, Huang K, Shi Z, et al. High beta-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression. Neuro Oncol 2011;13:600-609.
23. Yue X, Lan F, Yang W, et al. Interruption of beta-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells. Brain Res 2010;1366:27-37.
24. Wang Y, Chen L, Bao Z, et al. Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and beta-catenin signaling pathways. Oncol Rep 2011;26:1173-1180.
25. Rossi M, Magnoni L, Miracco C, et al. Beta-catenin and Gli1 are prognostic markers in glioblastoma. Cancer Biol Ther 2011;11:753-761.
26. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol 2002;4:39-43.
27. Shi Z, Qian X, Li L, et al. Nuclear Translocation of beta-catenin is Essential for Glioma Cell Survival. J Neuroimmune Pharm 2012; DOI: 10.1007/s11481-012-9354-3
28. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised led trials. Lancet 2012;379:1591-1601.
29. Sun F, Sui C, Teng L, Liu X, Meng Q, Li Y. Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres. Int J Pharm 2010;397:44-49.
30. Presmanes C, De Miguel L, Espada R, Alvarez C, Morales E, Torrado JJ. Effect of PLGA hydrophilia on the drug release and the hypoglucemic activity of different insulin-loaded PLGA microspheres. J Microencapsul 2011;28:791-798.
31. Cozar-Bernal MJ, Holgado MA, Arias JL, et al. Insulin-loaded PLGA microparticles: flow focusing versus double emulsion/solvent evaporation. J Microencapsul 2011;28:430-441.
32. Caporali S, Levati L, Starace G, et al. AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol 2008;74:173-183.
33. Gaspar N, Marshall L, Perryman L, et al. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 2010;70:9243-9252.
34. Prasad G, Sottero T, Yang X, et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 2011;13:384-392.
35. Sinnberg T, Lasithiotakis K, Niessner H, et al. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 2009;129:1500-1515.
36. Dauer DJ, Ferraro B, Song L, et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005;24:3397-3408.
37. Lo HW, Cao X, Zhu H, Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 2008;14:6042-6054.
38. Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007;67:2908-2911.
39. Li X, Lu X, Xu H, et al. Paclitaxel/tetrandrine coloaded nanoparticles effectively promote the apoptosis of gastric cancer cells based on "oxidation therapy". Mol Pharmaceut 2012;9:222-229.
40. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-142.
41. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012;246:379-400.